$EVOK
Evoke Pharma Inc

2021 Q1 Form 10-Q Financial Statement

#000156459021026996 Filed on May 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $90.42K $0.00
YoY Change
Cost Of Revenue $60.00K
YoY Change
Gross Profit $30.00K
YoY Change
Gross Profit Margin 33.18%
Selling, General & Admin $2.338M $1.330M
YoY Change 75.83% 9.0%
% of Gross Profit 7794.32%
Research & Development $277.8K $463.9K
YoY Change -40.1% -37.89%
% of Gross Profit 926.08%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.681M $1.794M
YoY Change 49.46% 140.16%
Operating Profit -$2.590M -$1.794M
YoY Change 44.42%
Interest Expense $123.3K $3.378K
YoY Change 3551.24%
% of Operating Profit
Other Income/Expense, Net -$15.05K $3.378K
YoY Change -545.38%
Pretax Income -$2.610M -$1.790M
YoY Change 45.81% -9.14%
Income Tax
% Of Pretax Income
Net Earnings -$2.605M -$1.790M
YoY Change 45.53% -8.9%
Net Earnings / Revenue -2881.52%
Basic Earnings Per Share
Diluted Earnings Per Share -$83.76K -$73.24K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.19M $4.130M
YoY Change 340.44% 2.48%
Cash & Equivalents $18.19M $4.133M
Short-Term Investments
Other Short-Term Assets $620.0K $400.0K
YoY Change 55.0% 3362.9%
Inventory $240.0K
Prepaid Expenses
Receivables $130.0K
Other Receivables $0.00
Total Short-Term Assets $19.18M $4.530M
YoY Change 323.4% 6.34%
LONG-TERM ASSETS
Property, Plant & Equipment $120.0K $110.0K
YoY Change 9.09% 10.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change
Total Long-Term Assets $116.0K $110.0K
YoY Change 5.41% 10.0%
TOTAL ASSETS
Total Short-Term Assets $19.18M $4.530M
Total Long-Term Assets $116.0K $110.0K
Total Assets $19.30M $4.640M
YoY Change 315.86% 6.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $690.0K $930.0K
YoY Change -25.81% 89.8%
Accrued Expenses $550.0K $790.0K
YoY Change -30.38% -1.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.249M $1.716M
YoY Change 264.11% 33.04%
LONG-TERM LIABILITIES
Long-Term Debt $5.000M $0.00
YoY Change
Other Long-Term Liabilities $240.0K
YoY Change
Total Long-Term Liabilities $5.236M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.249M $1.716M
Total Long-Term Liabilities $5.236M $0.00
Total Liabilities $11.48M $1.720M
YoY Change 567.71% 33.33%
SHAREHOLDERS EQUITY
Retained Earnings -$101.5M -$87.52M
YoY Change 15.96%
Common Stock $109.3M $90.44M
YoY Change 20.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.811M $2.922M
YoY Change
Total Liabilities & Shareholders Equity $19.30M $4.638M
YoY Change 316.05% 6.37%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$2.605M -$1.790M
YoY Change 45.53% -8.9%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.953M -$1.552M
YoY Change 90.29% -19.46%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $13.07M $21.25K
YoY Change 61406.61% -96.66%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 13.07M 21.25K
YoY Change 61406.61% -96.66%
NET CHANGE
Cash From Operating Activities -2.953M -1.552M
Cash From Investing Activities
Cash From Financing Activities 13.07M 21.25K
Net Change In Cash 10.12M -1.531M
YoY Change -760.97% 18.61%
FREE CASH FLOW
Cash From Operating Activities -$2.953M -$1.552M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2021Q1 us-gaap Assets
Assets
19295950
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
428794
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
561348
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13070154
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
4380545
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
310162
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
561348
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
310162
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
104484
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
141705
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
691225
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-3214623
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2338295
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
2680871
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
1793687
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2590450
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1793687
CY2021Q1 evok Forgiveness Of Paycheck Protection Loan And Accrued Interest
ForgivenessOfPaycheckProtectionLoanAndAccruedInterest
105130
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3164
CY2020Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3378
CY2021Q1 us-gaap Interest Expense
InterestExpense
123339
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3378
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
21250
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
2921648
CY2021Q1 evok Forgiveness Of Paycheck Protection Loan And Accrued Interest1
ForgivenessOfPaycheckProtectionLoanAndAccruedInterest1
-104168
CY2021Q1 evok Increase Decrease In Prepaid Deferred Expense Inventory And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseInventoryAndOtherAssets
-359617
CY2020Q1 evok Increase Decrease In Prepaid Deferred Expense Inventory And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseInventoryAndOtherAssets
-227089
CY2021Q1 evok Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
-604126
CY2020Q1 evok Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
-140941
CY2021Q1 evok Accrued Compensation
AccruedCompensation
587438
CY2020Q1 evok Accrued Compensation
AccruedCompensation
157896
CY2021Q1 evok Accrued Interest Expense
AccruedInterestExpense
122589
CY2020Q4 us-gaap Assets
Assets
9434048
CY2020Q4 us-gaap Liabilities
Liabilities
12648671
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
7811384
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19295950
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
3237
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11551
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2662
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
109298703
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9434048
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
141705
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1273572
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1016232
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
119926
CY2020Q4 evok Paycheck Protection Program Loan
PaycheckProtectionProgramLoan
104168
CY2021Q1 evok Milestone Payable
MilestonePayable
5000000
CY2020Q4 evok Milestone Payable
MilestonePayable
5000000
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9038
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
6248983
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7535677
CY2021Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
5000000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
5000000
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
235583
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
112994
CY2021Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5235583
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5112994
CY2021Q1 us-gaap Liabilities
Liabilities
11484566
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
95667776
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101490556
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-98885061
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32371954
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26621954
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32371954
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26621954
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
90421
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2605495
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15045
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1790309
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1329834
CY2021Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
277825
CY2020Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
463853
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1304846
CY2021Q1 evok Increase Decrease In Deferred Rent Expense
IncreaseDecreaseInDeferredRentExpense
-9038
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2953119
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1551895
CY2021Q1 us-gaap Loans Assumed1
LoansAssumed1
104168
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1530645
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13070154
CY2020Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
21250
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13070154
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21250
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10117035
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5663833
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4133188
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. </p>
CY2021Q1 evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2021Q1 evok Bad Debt Expense
BadDebtExpense
0
CY2021Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
151000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
151000
CY2021Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
85000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
85000
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
CY2017Q4 evok Common Stock Shares To Be Issued Value
CommonStockSharesToBeIssuedValue
16000000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4300000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M2D

Files In Submission

Name View Source Status
0001564590-21-026996-index-headers.html Edgar Link pending
0001564590-21-026996-index.html Edgar Link pending
0001564590-21-026996.txt Edgar Link pending
0001564590-21-026996-xbrl.zip Edgar Link pending
evok-10q_20210331.htm Edgar Link pending
evok-20210331.xml Edgar Link completed
evok-20210331.xsd Edgar Link pending
evok-20210331_cal.xml Edgar Link unprocessable
evok-20210331_def.xml Edgar Link unprocessable
evok-20210331_lab.xml Edgar Link unprocessable
evok-20210331_pre.xml Edgar Link unprocessable
evok-ex311_6.htm Edgar Link pending
evok-ex312_10.htm Edgar Link pending
evok-ex321_12.htm Edgar Link pending
evok-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gmyeixoxypmh000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending